Thermo Fisher Scientific Inc. (NYSE:TMO) Announces Quarterly Dividend of $0.43

Thermo Fisher Scientific Inc. (NYSE:TMO) declared a quarterly dividend on Wednesday, May 21st, RTT News reports. Shareholders of record on Friday, June 13th will be given a dividend of 0.43 per share by the medical research company on Tuesday, July 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th.

Thermo Fisher Scientific has a dividend payout ratio of 7.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Thermo Fisher Scientific to earn $25.56 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 6.7%.

Thermo Fisher Scientific Trading Up 1.5%

Shares of Thermo Fisher Scientific stock opened at $414.53 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a fifty day simple moving average of $418.02 and a 200 day simple moving average of $494.38. Thermo Fisher Scientific has a 12-month low of $390.50 and a 12-month high of $627.88. The company has a market capitalization of $156.48 billion, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.11 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Scotiabank decreased their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research report on Friday, April 25th. UBS Group decreased their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a report on Thursday, April 24th. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Finally, Citigroup reduced their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 491 shares of the medical research company’s stock after buying an additional 20 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.